等待开盘 11-19 09:30:00 美东时间
0.000
0.00%
Cardiff Oncology announced positive Phase 2 trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus 11 months in the control arm. All patients in the 30 mg arm have exceeded 21 months on treatment. The company plans to initiate a registrational Phase 3 trial in Q1 2027, targeting first-line RAS-mutated mCRC. Cardiff also reported $33...
11-12 12:00
AIM ImmunoTech Inc. has released a new investor presentation highlighting the potential of combining Ampligen (rintatolimod) with Revolution Medicines' Rasonque™ (daraxonrasib) to enhance and prolong clinical benefits in pancreatic cancer treatment. The presentation emphasizes Ampligen's immune-stimulating activity and daraxonrasib's targeted RAS inhibition, supported by clinical observations and ongoing trials. Key highlights include Phase 3 res...
11-05 14:13
Oncolytics Biotech Inc. reported updated data from Cohort 4 of its Phase 1/2 GOBLET study, showing pelareorep combined with atezolizumab achieved a median duration of response of approximately 15 months in second-line squamous cell anal cancer patients, exceeding historical results of 9.5 months for approved monotherapy. All responding patients survived over one year, with some exceeding 24 months. The FDA's Fast Track Designation and regulatory ...
10-27 13:30
<p>At the 2026 ESMO Congress, BioNTech will present new clinical data from its late-stage oncology pipeline, including updates on pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, in combination with docetaxel for second-line metastatic non-small cell lung cancer (NSCLC). Additionally, data on pumitamig combined with elfetabart drozuntecan, a B7-H3-targeting antibody-drug conjugate, will be showcased across multiple advanced solid tumors. The...
10-19 10:45
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
06-08 20:36
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients with P53WT genomics
06-01 19:07